Semapimod | 352513-83-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Semapimod
• 英文别名: N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide
• CAS: 352513-83-8
• 化学式: C₃₄H₅₂N₁₈O₂
• 分子量: 744.9
• InChiKey: PWDYHMBTPGXCSN-VCBMUGGBSA-N

物化性质

• 密度：
  1.39

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  54
• 可旋转键数：
  19
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  365
• 氢给体数：
  10
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  hydrogen N,N'-bis[3,5-diethanoylphenyl]decanediamide 、 肼甲酰亚胺酰胺一氯化氢 在 肼甲酰亚胺酰胺一氯化氢 作用下， 以76的产率得到Semapimod
  参考文献：
  名称：

  Arch. Pharm. Chem. Life Sci. 2016, 349, 91-103

  摘要：

  DOI：

文献信息

• NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS
  申请人：Kyoto Prefectural Public University Corporation

  公开号：EP2799537A1

  公开（公告）日：2014-11-05

  The present invention provides a method for the normalized culturing ofcorneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) β signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.

  本发明提供了一种角膜内皮细胞正常化培养的方法。更具体地说，本发明提供了一种角膜内皮细胞正常化培养剂，其中包括一种纤维化抑制剂。具体而言，本发明提供了一种培养正常化制剂，其中包括一种转化生长因子（TGF）β 信号抑制剂。本发明还提供了一种用于正常培养角膜内皮细胞的培养基，它包括根据本发明的培养正常化剂和角膜内皮培养成分。本发明还提供了一种正常培养角膜内皮细胞的方法，包括使用根据本发明的培养归一化剂或根据本发明的培养基培养角膜内皮细胞的步骤。
• DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE
  申请人：The Doshisha

  公开号：EP3069732A1

  公开（公告）日：2016-09-21

  Provided is an agent for treating or preventing a corneal endothelial disorder wherein cell proliferation is required. More specifically, provided is an agent for treating or preventing a corneal endothelial disorder, wherein cell proliferation is required, said agent comprising a p38MAP kinase inhibitor. In a preferred embodiment, the corneal endothelial disorder is a wound. In a preferred embodiment, the p38MAP kinase inhibitor is soluble in water. The p38MAP kinase inhibitor may comprise 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazo le-5-yl]pyridine (SB203580) or a salt thereof.

  本发明提供了一种用于治疗或预防角膜内皮失调的制剂，其中需要细胞增殖。更具体地说，提供了一种用于治疗或预防角膜内皮紊乱的制剂，其中需要细胞增殖，所述制剂包括 p38MAP 激酶抑制剂。在一个优选的实施方案中，角膜内皮失调是一种伤口。在一个优选的实施方案中，p38MAP 激酶抑制剂可溶于水。p38MAP 激酶抑制剂可包括 4-[4-(4-氟苯基)-2-(4-甲亚磺酰基苯基)-1H-咪唑-5-基]吡啶 (SB203580) 或其盐。
• DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALS, AND APPLICATION THEREOF
  申请人：The Doshisha

  公开号：EP3381472A1

  公开（公告）日：2018-10-03

  Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

  本发明提供了一种利用p38 MAP激酶抑制剂治疗或预防角膜内皮细胞中由转化生长因子-β（TGF-β）信号、线粒体异常和/或内质网（ER）相关应激引起的角膜内皮细胞状况、失调或疾病的药物或方法。本发明提供了一种药物，其中包括 p38 MAP 激酶抑制剂，用于治疗或预防由角膜内皮细胞中的 TGF-β 信号和/或线粒体异常引起的角膜内皮的状况、紊乱或疾病。在优选的实施方案中，角膜内皮的状况、失调或疾病是福氏角膜内皮营养不良症。
• Medicament for treatment of liver cancer
  申请人：Zender Lars

  公开号：US10441577B2

  公开（公告）日：2019-10-15

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。
• Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
  申请人：THE DOSHISHA

  公开号：US10813920B2

  公开（公告）日：2020-10-27

  Provided is an agent for treating or preventing a corneal endothelial disorder wherein cell proliferation is required. More specifically, provided is an agent for treating or preventing a corneal endothelial disorder, wherein cell proliferation is required, said agent comprising a p38MAP kinase inhibitor. In a preferred embodiment, the corneal endothelial disorder is a wound. In a preferred embodiment, the p38MAP kinase inhibitor is soluble in water. The p38MAP kinase inhibitor may comprise 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) or a salt thereof.

  本发明提供了一种用于治疗或预防角膜内皮失调的制剂，其中需要细胞增殖。更具体地说，提供了一种用于治疗或预防角膜内皮紊乱的制剂，其中需要细胞增殖，所述制剂包括 p38MAP 激酶抑制剂。在一个优选的实施方案中，角膜内皮失调是一种伤口。在一个优选的实施方案中，p38MAP 激酶抑制剂可溶于水。p38MAP激酶抑制剂可包括4-(4-氟苯基)-2-(4-甲磺酰基苯基)-5-(4-吡啶基)-1H-咪唑(SB203580)或其盐。